首页> 外文期刊>Research journal of pharmacy and technology >Formulation and In-vitro Characterization of Self Nano-emulsifying Drug Delivery System (SNEDDS) for enhanced Solubility of Candesartan Cilexetil
【24h】

Formulation and In-vitro Characterization of Self Nano-emulsifying Drug Delivery System (SNEDDS) for enhanced Solubility of Candesartan Cilexetil

机译:自纳米乳化药物递送系统(SNEDDS)的配方和体外表征,用于增强Candesartan型纤维曲线的溶解度

获取原文
获取原文并翻译 | 示例

摘要

Candesartan cilexetil is the prodrug of candesartan, a selective angiotensin II receptor antagonist, used in the management of hypertension and heart failure. It is characterized by poor aqueous solubility resulting in low bioavailability. Self-nanoemulsifying drug delivery systems (SNEDDS) loaded with candesartan cilexetil were successfully developed to overcome such obstacles. Preliminary screening was carried out to select proper oil, surfactant and co-surfactant combination for successful SNEDDS formulation. Ternary and pseudo ternary diagrams were constructed to optimize the system. Capryol 90? as an oil showed high emulsification ability. The nature of obtained dispersions was found to be nanoemulsions. Six formulations were visually inspected and evaluated for stability, robustness to dilution, effect of drug loading on the nano-emulsion boundary, viscosity, content uniformity, their mean droplet size, polydispersity index (PDI), zeta potential in addition to in vitro drug release study. Three formulations showed a very short emulsification time of less than 3minutes. The emulsification efficiency was significantly superior at pH6.8. All selected formulations showed mean droplet size (124.25 to 460.15nm), very low PDI values (0.311-0.562) and zeta potential (30.5-44.45 mV). Formulation F16 (10% w/w Capryol 90?, 30% w/w Tween80, 60% w/w Transcutol?) was- selected for further characterization. Droplet size of F16 showed robustness to different dilution folds with different media. These results indicate that, SNEDDS could be promising delivery systems with a rapid onset of action and prolonged therapeutic effect of candesartan cilexetil.
机译:Candesartan Cilexetil是Candaartan的前药,一种选择性血管紧张素II受体拮抗剂,用于管理高血压和心力衰竭。其特征在于差的水溶性导致低生物利用度。成功地开发了用坎德坦纤维克雷替尼尔装载的自纳中乳化药物递送系统(SNEDDS)以克服此类障碍。进行初步筛选,以选择适当的油,表面活性剂和共表面活性剂组合,用于成功的SnEdds配方。构建三元和伪三元图以优化系统。辛醇90?由于油显示出高乳化能力。发现获得的分散体的性质是纳米乳液。目视检查和评价六种制剂,对稳定性,鲁棒性稀释,药物负载对纳米乳液边界的影响,粘度,含量均匀性,其平均液滴尺寸,多分散性指数(PDI),Zeta电位除了体外药物释放学习。三种制剂显示出非常短的乳化时间小于3分钟。乳化效率在pH6.8下显着优于优异。所有选定的配方显示平均液滴尺寸(124.25至460.15nm),非常低的PDI值(0.311-0.562)和Zeta电位(30.5-44.45 mV)。选择F16(10%w / w氯化钴90-,30%w / w tween80,60%w / w trancutolα),用于进一步表征。 F16的液滴尺寸向不同介质的不同稀释折叠显示了鲁棒性。这些结果表明,Snedds可能是有前途的递送系统,其作用快速发作,达到Candaartan Cilexetil的延长治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号